GeneFerm Biotechnology Co Ltd (1796) - Total Assets
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) holds total assets worth NT$1.25 Billion TWD (≈ $39.29 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GeneFerm Biotechnology Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see GeneFerm Biotechnology Co Ltd (1796) total market value for the company's overall valuation and market capitalisation.
GeneFerm Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
GeneFerm Biotechnology Co Ltd's total assets of NT$1.25 Billion consist of 35.9% current assets and 64.1% non-current assets. Review 1796 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 10.7% |
| Accounts Receivable | NT$87.84 Million | 7.7% |
| Inventory | NT$165.87 Million | 14.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 1796 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneFerm Biotechnology Co Ltd's current assets represent 35.9% of total assets in 2024, a decrease from 46.4% in 2017.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, down from 13.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 14.5% of total assets.
GeneFerm Biotechnology Co Ltd Competitors by Total Assets
Key competitors of GeneFerm Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
GeneFerm Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.03 | 2.35 | 5.30 |
| Quick Ratio | 2.76 | 1.52 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$407.33 Million | NT$278.87 Million | NT$434.54 Million |
GeneFerm Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between GeneFerm Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | NT$1.15 Billion |
| Market Capitalization | $38.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values GeneFerm Biotechnology Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: GeneFerm Biotechnology Co Ltd's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual total assets of GeneFerm Biotechnology Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.15 Billion ≈ $36.12 Million |
-2.46% |
| 2023-12-31 | NT$1.18 Billion ≈ $37.03 Million |
-1.20% |
| 2022-12-31 | NT$1.19 Billion ≈ $37.48 Million |
-9.66% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.49 Million |
+34.02% |
| 2020-12-31 | NT$982.58 Million ≈ $30.96 Million |
-1.79% |
| 2019-12-31 | NT$1.00 Billion ≈ $31.52 Million |
+79.56% |
| 2018-12-31 | NT$557.20 Million ≈ $17.55 Million |
+9.52% |
| 2017-12-31 | NT$508.75 Million ≈ $16.03 Million |
-- |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more